

Joel R Lexchin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/57761/publications.pdf>

Version: 2024-02-01

255
papers

8,781
citations

101384

36
h-index

56606

83
g-index

259
all docs

259
docs citations

259
times ranked

7395
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Antidepressants are not safe during pregnancy and in women of childbearing age. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2447-2448. | 1.1 | 2 |
| 2 | Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. <i>BMJ Quality and Safety</i> , 2022, 31, 179-190. | 1.8 | 6 |
| 3 | COVID-19 Vaccine Task Force and Conflicts of Interest. <i>Healthcare Policy</i> , 2022, 17, 20-27. | 0.3 | 3 |
| 4 | Pharmaceutical Company Payments to Healthcare Professionals and Healthcare Organizations in Canada: An Observational Study. <i>Healthcare Policy</i> , 2022, 17, 42-48. | 0.3 | 1 |
| 5 | National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study. <i>BMJ Open</i> , 2022, 12, e055287. | 0.8 | 1 |
| 6 | Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. <i>Drug Safety</i> , 2022, , 1. | 1.4 | 2 |
| 7 | Use of priority and provisional approval pathways by the Australian Therapeutic Goods Administration in approving new medicines: a cross-sectional study. <i>Australian Health Review</i> , 2022, 46, 309-315. | 0.5 | 1 |
| 8 | Sponsorship of Canadian Professional Medical Societies by Drug, Medical Device and Medical Technology Companies: a Cross-sectional Study. <i>Journal of General Internal Medicine</i> , 2022, , . | 1.3 | 1 |
| 9 | After More Than 50 Years, Pharmcare (and Dental Care) are Coming to Canada. <i>International Journal of Health Services</i> , 2022, 52, 341-346. | 1.2 | 4 |
| 10 | Sponsorship of Australian and New Zealand medical societies by healthcare companies: an observational study. <i>JRSM Open</i> , 2022, 13, 205427042211112. | 0.2 | 0 |
| 11 | Drug Promotion in India Since 2000: Problems Remain. <i>International Journal of Health Services</i> , 2021, 51, 392-403. | 1.2 | 2 |
| 12 | Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1424-1442. | 2.3 | 12 |
| 13 | Pharmaceuticals as a market for "celebrations": Theory and practice. <i>Social Science and Medicine</i> , 2021, 268, 113368. | 1.8 | 8 |
| 14 | Time to Marketing of Generic Drugs After Patent Expiration in Canada. <i>JAMA Network Open</i> , 2021, 4, e211143. | 2.8 | 3 |
| 15 | A Ray of Sunshine: Transparency in Physician-Industry Relationships Is Not Enough. <i>Journal of General Internal Medicine</i> , 2021, 36, 3194-3198. | 1.3 | 25 |
| 16 | Achieving greater independence from commercial influence in research. <i>BMJ</i> , The, 2021, 372, n370. | 3.0 | 12 |
| 17 | Companies' statements about drugs withdrawn from the Canadian market: A descriptive analysis. <i>International Journal of Risk and Safety in Medicine</i> , 2021, 32, 331-341. | 0.3 | 1 |
| 18 | The potential benefits of a national vaccine registry for Canada. <i>Cmaj</i> , 2021, 193, E808-E808. | 0.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Time to market for drugs approved in Canada between 2014 and 2018: an observational study. <i>BMJ Open</i> , 2021, 11, e047557. | 0.8 | 4 |
| 20 | Health Canada: optimizing transparency and its impact for patients. <i>Cmaj</i> , 2021, 193, E1503-E1503. | 0.9 | 0 |
| 21 | Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19. <i>International Journal of Health Services</i> , 2021, 51, 5-13. | 1.2 | 11 |
| 22 | A sorry tale of unnecessary secrecy about medicine safety. <i>Internal Medicine Journal</i> , 2021, 51, 1765-1766. | 0.5 | 0 |
| 23 | A comparison of the Food and Drug Administration's and Health Canada's regulatory decisions about failed confirmatory trials for oncology drugs: an observational study. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 93. | 1.1 | 0 |
| 24 | Are academia's pharma partnerships essential for novel drug discovery in the time of the COVID-19 pandemic?. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 475-479. | 2.5 | 5 |
| 25 | The costs of coronavirus vaccines and their pricing. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 502-504. | 1.1 | 31 |
| 26 | Donations Made and Received: A Study of Disclosure Practices of Pharmaceutical Companies and Patient Groups in Canada. <i>International Journal of Health Policy and Management</i> , 2021, , . | 0.5 | 0 |
| 27 | Industry involvement in clinical practice guidelines. <i>Canadian Family Physician</i> , 2021, 67, 721.4-724. | 0.1 | 1 |
| 28 | Does an Orphan Drug Policy Make a Difference in Access? A Comparison of Canada and Australia. <i>International Journal of Health Services</i> , 2020, 50, 166-172. | 1.2 | 4 |
| 29 | Baclofen and Alcohol Use Disorders: Breakthrough or Great White Elephant?. <i>Alcohol and Alcoholism</i> , 2020, 55, 49-50. | 0.9 | 6 |
| 30 | Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature. <i>Health Policy</i> , 2020, 124, 231-238. | 1.4 | 1 |
| 31 | COVID-19: still much to learn. <i>Journal of the Royal Society of Medicine</i> , 2020, 113, 244-244. | 1.1 | 0 |
| 32 | Financial conflict of interest among clinical practice guideline-producing organisations. <i>British Journal of General Practice</i> , 2020, 70, 530-531. | 0.7 | 1 |
| 33 | A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States 2007 to 2016. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1054-1063. | 0.9 | 9 |
| 34 | Who assigns value in value-based insurance design?. <i>Cmaj</i> , 2020, 192, E15-E15. | 0.9 | 0 |
| 35 | Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020, 60, 840-851. | 0.4 | 36 |
| 36 | Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study. <i>BMJ Open</i> , 2020, 10, e035633. | 0.8 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study. <i>BMJ Open</i> , 2020, 10, e034993. | 0.8 | 9 |
| 38 | Affordable Biologics for All. <i>JAMA Network Open</i> , 2020, 3, e204753. | 2.8 | 8 |
| 39 | The Rise and Fall of the Neurotic Housewife: Patient Sex in Psychotropic Drug Advertising to Physicians 1946–1990. <i>International Journal of Health Services</i> , 2020, 50, 292-298. | 1.2 | 1 |
| 40 | Restoring the Bacloville trial: efficacy and harms. <i>Addiction</i> , 2020, 115, 2184-2186. | 1.7 | 6 |
| 41 | Financial ties between leaders of influential US professional medical associations and industry: cross sectional study. <i>BMJ</i> , 2020, 369, m1505. | 3.0 | 49 |
| 42 | Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study. <i>Cmaj</i> , 2020, 192, E617-E625. | 0.9 | 28 |
| 43 | The “Nuts and Bolts” of Opioid Marketing: Promotional Messages to Family Doctors in Sacramento, Vancouver, Montreal, and Toulouse. <i>Journal of General Internal Medicine</i> , 2020, 35, 3730-3732. | 1.3 | 1 |
| 44 | Information and promotional strategies by pharmaceutical companies for clinicians. <i>The Cochrane Library</i> , 2020, , . | 1.5 | 0 |
| 45 | Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009. <i>Systematic Reviews</i> , 2020, 9, 77. | 2.5 | 11 |
| 46 | How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study. <i>PLoS ONE</i> , 2020, 15, e0240966. | 1.1 | 4 |
| 47 | Development Time and Patent Extension for Prescription Drugs in Canada: A Cohort Study. <i>International Journal of Health Policy and Management</i> , 2020, , . | 0.5 | 2 |
| 48 | Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19. <i>Journal of Law and the Biosciences</i> , 2020, 7, lsa083. | 0.8 | 5 |
| 49 | Health Canada’s Proposal to Accelerate New Drug Reviews. <i>Healthcare Policy</i> , 2020, 15, 26-34. | 0.3 | 0 |
| 50 | It’s Time to Finally Kill the Zombies Comment on "Universal Pharmacare in Canada". <i>International Journal of Health Policy and Management</i> , 2020, 9, 528-530. | 0.5 | 1 |
| 51 | Engaging physicians to prescribe more cost-effectively: Blueprint for change. <i>Canadian Family Physician</i> , 2020, 66, 723-725. | 0.1 | 0 |
| 52 | Title is missing!. , 2020, 15, e0240966. | | 0 |
| 53 | Title is missing!. , 2020, 15, e0240966. | | 0 |
| 54 | Title is missing!. , 2020, 15, e0240966. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Title is missing!. , 2020, 15, e0240966. | | 0 |
| 56 | Financial costs associated with monopolies on biologic medicines in Australia. Australian Health Review, 2019, 43, 36. | 0.5 | 16 |
| 57 | Medicines Information and the Regulation of the Promotion of Pharmaceuticals. Science and Engineering Ethics, 2019, 25, 1167-1192. | 1.7 | 39 |
| 58 | Declarations of interest by members of Health Canada's special advisory committees and panels: a descriptive study. CMAJ Open, 2019, 7, E334-E340. | 1.1 | 6 |
| 59 | Pharmaceutical Industry's "Initiated Postapproval Studies" Not Requested by the US FDA, Little Value, and Many Questions. JAMA Network Open, 2019, 2, e193392. | 2.8 | 0 |
| 60 | Innovation and off-label use, the French case and more. British Journal of Clinical Pharmacology, 2019, 85, 2446-2447. | 1.1 | 3 |
| 61 | The "pharmaceuticalisation" of life. BMJ: British Medical Journal, 2019, 365, l1972. | 2.4 | 7 |
| 62 | Canada finally opens up data on new drugs and devices. BMJ: British Medical Journal, 2019, 365, l1825. | 2.4 | 7 |
| 63 | Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom. JAMA Internal Medicine, 2019, 179, 982. | 2.6 | 21 |
| 64 | Secret safety warnings on medicines: A case study of information access requests. Pharmacoepidemiology and Drug Safety, 2019, 28, 551-555. | 0.9 | 6 |
| 65 | Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study. PLoS ONE, 2019, 14, e0212399. | 1.1 | 15 |
| 66 | An International Mapping of Medical Care in Nursing Homes. Health Services Insights, 2019, 12, 117863291882508. | 0.6 | 7 |
| 67 | Health Canada's Use of its Notice of Compliance With Conditions Drug Approval Policy: A Retrospective Cohort Analysis. International Journal of Health Services, 2019, 49, 294-305. | 1.2 | 7 |
| 68 | Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study. BMJ Open, 2019, 9, e030750. | 0.8 | 6 |
| 69 | The impact of post-market regulatory safety advisories on patients, prescribers, and the healthcare system. The Cochrane Library, 2019, , . | 1.5 | 1 |
| 70 | Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts. Globalization and Health, 2019, 15, 78. | 2.4 | 33 |
| 71 | National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism. Obstetrics and Gynecology, 2019, 134, 1115-1117. | 1.2 | 1 |
| 72 | Pathways to independence: towards producing and using trustworthy evidence. BMJ, The, 2019, 367, l6576. | 3.0 | 79 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Increase in Drug Spending in Canada Due to Extension of Data Protection for Biologics: A Descriptive Study. <i>Healthcare Policy</i> , 2019, 14, 10-18. | 0.3 | 3 |
| 74 | Enabling Patient Portals to Access Primary Care Medical Records: Maximizing Collaboration in Care Between Patients and Providers. <i>Healthcare Policy</i> , 2019, 14, 21-27. | 0.3 | 4 |
| 75 | Direct-to-consumer advertising of prescription medications: what the Canadian medical trainee needs to know. <i>Canadian Medical Education Journal</i> , 2019, 10, e113-e116. | 0.3 | 0 |
| 76 | Can direct-to-consumer advertising of prescription drugs be effectively regulated?. <i>New Zealand Medical Journal</i> , 2019, 132, 59-65. | 0.5 | 1 |
| 77 | Nursing Home Physicians Discuss Caring for Elderly Residents: An Exploratory Study. <i>Canadian Journal on Aging</i> , 2018, 37, 133-144. | 0.6 | 7 |
| 78 | Reconciling a "pleasant exchange" with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care. <i>Health Policy</i> , 2018, 122, 250-255. | 1.4 | 5 |
| 79 | Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis. <i>Journal of Pharmaceutical Policy and Practice</i> , 2018, 11, 5. | 1.1 | 24 |
| 80 | The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries. <i>Global Social Policy</i> , 2018, 18, 7-27. | 1.0 | 29 |
| 81 | Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study. <i>BMJ Open</i> , 2018, 8, e020377. | 0.8 | 8 |
| 82 | Cost recovery by Health Canada and drug safety: a time-series analysis. <i>CMAJ Open</i> , 2018, 6, E471-E477. | 1.1 | 0 |
| 83 | Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario. <i>International Journal of Health Services</i> , 2018, 48, 702-715. | 1.2 | 2 |
| 84 | Ten Principles for More Conservative, Care-Full Diagnosis. <i>Annals of Internal Medicine</i> , 2018, 169, 643. | 2.0 | 37 |
| 85 | Canadian status of "drugs to avoid" in 2017: a descriptive analysis. <i>CMAJ Open</i> , 2018, 6, E430-E435. | 1.1 | 3 |
| 86 | Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence. <i>Globalization and Health</i> , 2018, 14, 86. | 2.4 | 5 |
| 87 | Health Canada's use of expedited review pathways and therapeutic innovation, 1995-2016: cross-sectional analysis. <i>BMJ Open</i> , 2018, 8, e023605. | 0.8 | 19 |
| 88 | Healing an ailing pharmaceutical system: prescription for reform for United States and Canada. <i>BMJ: British Medical Journal</i> , 2018, 361, k1039. | 2.4 | 17 |
| 89 | A call to mandate patient access to personal primary care medical records across Canada. <i>Cmaj</i> , 2018, 190, E869-E870. | 0.9 | 8 |
| 90 | Industry sponsorship and research outcome: systematic review with meta-analysis. <i>Intensive Care Medicine</i> , 2018, 44, 1603-1612. | 3.9 | 97 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Combating corruption in the pharmaceutical arena. Indian Journal of Medical Ethics, 2018, 3, 234-239. | 0.2 | 6 |
| 92 | The term is misleading. Canadian Family Physician, 2018, 64, 792. | 0.1 | 0 |
| 93 | Industry sponsorship and research outcome. The Cochrane Library, 2017, 2017, MR000033. | 1.5 | 772 |
| 94 | Medicines Save, Medicines Kill. Drug Safety, 2017, 40, 457-459. | 1.4 | 1 |
| 95 | Myths and Realities About Why Prescription Drug Prices in the United States Are So High. Pharmaceutical Medicine, 2017, 31, 143-148. | 1.0 | 0 |
| 96 | Conflicts of Interest and the Presence of Methodologists on Guideline Development Panels: A Cross-Sectional Study of Clinical Practice Guidelines for Major Depressive Disorder. Psychotherapy and Psychosomatics, 2017, 86, 168-170. | 4.0 | 19 |
| 97 | Drug prices: How do we get to a better place?. Cmaj, 2017, 189, E792-E793. | 0.9 | 2 |
| 98 | Continuing medical education and pharmaceutical industry involvement: An evaluation of policies adopted by Canadian professional medical associations. International Journal of Risk and Safety in Medicine, 2017, 29, 1-16. | 0.3 | 7 |
| 99 | The relation between promotional spending on drugs and their therapeutic gain: a cohort analysis. CMAJ Open, 2017, 5, E724-E728. | 1.1 | 16 |
| 100 | Developing a Clinician Friendly Tool to Identify Useful Clinical Practice Guidelines: G-TRUST. Annals of Family Medicine, 2017, 15, 413-418. | 0.9 | 24 |
| 101 | Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study. Value in Health, 2017, 20, 1139-1142. | 0.1 | 7 |
| 102 | We need to mandate drug cost transparency on electronic medical records. Cmaj, 2017, 189, E1541-E1542. | 0.9 | 9 |
| 103 | Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis. BMJ Open, 2017, 7, e018372. | 0.8 | 1 |
| 104 | Priority reviews: innovation and safety. Cmaj, 2017, 189, E895-E895. | 0.9 | 0 |
| 105 | Publication of confirmatory studies required by Health Canada for drugs approved under a Notice of Compliance with conditions: a cohort study. CMAJ Open, 2017, 5, E295-E300. | 1.1 | 3 |
| 106 | The Pharmaceutical Industry and the Canadian Government: Folie À Deux. Healthcare Policy, 2017, 13, 10-16. | 0.3 | 0 |
| 107 | Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?. British Journal of Clinical Pharmacology, 2017, 83, 2549-2556. | 1.1 | 5 |
| 108 | Skilled use of the media by vested interests to promote drugs and other health products. BMJ, The, 2016, 352, i1179. | 3.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study. Healthcare Policy, 2016, 12, 65-75. | 0.3 | 9 |
| 110 | The Need to Systematically Evaluate Clinical Practice Guidelines. Journal of the American Board of Family Medicine, 2016, 29, 644-648. | 0.8 | 22 |
| 111 | Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase. BMC Health Services Research, 2016, 16, 383. | 0.9 | 26 |
| 112 | Observational Evidence of For-Profit Delivery and Inferior Nursing Home Care: When Is There Enough Evidence for Policy Change?. PLoS Medicine, 2016, 13, e1001995. | 3.9 | 48 |
| 113 | Off-label drug use and temporary recommendations for use: Rearranging the deckchairs on the Titanic?. Health Policy, 2016, 120, 890-891. | 1.4 | 6 |
| 114 | Hippocrates and Targin. Cmaj, 2016, 188, 1262.2-1262. | 0.9 | 0 |
| 115 | Analysis of the Drugs Withdrawn from the US Market from 1976 to 2010 for Safety Reasons. Pharmaceutical Medicine, 2016, 30, 277-289. | 1.0 | 12 |
| 116 | “Adaptive pathways” to drug authorisation: adapting to industry?. BMJ, The, 2016, 354, i4437. | 3.0 | 38 |
| 117 | The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia. International Journal of Health Services, 2016, 46, 597-613. | 1.2 | 16 |
| 118 | Off-Label Drug Use. American Journal of Medical Quality, 2016, 31, 285-285. | 0.2 | 8 |
| 119 | A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada. Healthcare Policy, 2016, 12, 18-36. | 0.3 | 12 |
| 120 | How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study. Healthcare Policy, 2016, 12, 65-75. | 0.3 | 8 |
| 121 | Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study. CMAJ Open, 2015, 3, E286-E291. | 1.1 | 3 |
| 122 | The effect of early in-hospital medication review on health outcomes: a systematic review. British Journal of Clinical Pharmacology, 2015, 80, 51-61. | 1.1 | 44 |
| 123 | Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: A cohort study. International Journal of Risk and Safety in Medicine, 2015, 27, 135-142. | 0.3 | 1 |
| 124 | Why do cancer drugs get such an easy ride?. BMJ, The, 2015, 350, h2068-h2068. | 3.0 | 36 |
| 125 | Health Canada's use of its priority review process for new drugs: a cohort study. BMJ Open, 2015, 5, e006816-e006816. | 0.8 | 30 |
| 126 | Clinical trial transparency: many gains but access to evidence for new medicines remains imperfect. British Medical Bulletin, 2015, 116, ldv042. | 2.7 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Why are there deadly drugs?. BMC Medicine, 2015, 13, 27. | 2.3 | 5 |
| 128 | Can reporting of adverse drug reactions create safer systems while improving health data?. Cmaj, 2015, 187, 789-790. | 0.9 | 15 |
| 129 | Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy. British Journal of Clinical Pharmacology, 2015, 79, 847-859. | 1.1 | 35 |
| 130 | The FDA's new clothes. BMJ, The, 2015, 351, h4897. | 3.0 | 11 |
| 131 | A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. Health Policy, 2015, 119, 802-813. | 1.4 | 51 |
| 132 | Complete dissociation from the health care and pharmaceutical industry. Canadian Family Physician, 2015, 61, 668-9. | 0.1 | 1 |
| 133 | Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study. BMJ Open, 2014, 4, e004289. | 0.8 | 5 |
| 134 | Legislative regulation and ethical governance of medical research in different European Union countries. Journal of Medical Ethics, 2014, 40, 409-413. | 1.0 | 31 |
| 135 | A compromise too far: A review of Canadian cases of direct-to-consumer advertising regulation. International Journal of Risk and Safety in Medicine, 2014, 26, 213-225. | 0.3 | 14 |
| 136 | From <i>caveat emptor</i> to <i>caveat venditor</i> : time to stop the influence of money on practice guideline development. Journal of Evaluation in Clinical Practice, 2014, 20, 809-812. | 0.9 | 19 |
| 137 | CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs. Globalization and Health, 2014, 10, 30. | 2.4 | 24 |
| 138 | Differences in the Volume of Pharmaceutical Advertisements between Print General Medical Journals. PLoS ONE, 2014, 9, e84790. | 1.1 | 9 |
| 139 | Quality and Quantity of Information in Summary Basis of Decision Documents Issued by Health Canada. PLoS ONE, 2014, 9, e92038. | 1.1 | 10 |
| 140 | How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009. Open Medicine, 2014, 8, e14-9. | 1.5 | 12 |
| 141 | Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews. BMC Health Services Research, 2013, 13, 88. | 0.9 | 18 |
| 142 | Pharmaceutical Sales Representatives and Patient Safety. Journal of General Internal Medicine, 2013, 28, 1395-1395. | 1.3 | 2 |
| 143 | Canada and access to medicines in developing countries: intellectual property rights first. Globalization and Health, 2013, 9, 42. | 2.4 | 4 |
| 144 | What do Canadians think about physician-pharmaceutical industry interactions?. Health Policy, 2013, 112, 255-263. | 1.4 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Pharmaceutical Sales Representatives and Patient Safety: A Comparative Prospective Study of Information Quality in Canada, France and the United States. <i>Journal of General Internal Medicine</i> , 2013, 28, 1368-1375. | 1.3 | 79 |
| 146 | Who should fund CME?. <i>Canadian Journal of Emergency Medicine</i> , 2013, 15, 133. | 0.5 | 0 |
| 147 | Opioid abuse. <i>Cmaj</i> , 2013, 185, 418.2-418. | 0.9 | 0 |
| 148 | Surrogate Outcomes in Clinical Trials. <i>JAMA Internal Medicine</i> , 2013, 173, 611. | 2.6 | 109 |
| 149 | Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs. <i>Journal of Law, Medicine and Ethics</i> , 2013, 41, 590-600. | 0.4 | 112 |
| 150 | Provincial Drug Plan Officials' Views of the Canadian Drug Safety System. <i>Journal of Health Politics, Policy and Law</i> , 2013, 38, 545-571. | 0.9 | 6 |
| 151 | Economics and industry do not mean ethical conduct in clinical trials. <i>Journal of Pharmaceutical Policy and Practice</i> , 2013, 6, 11. | 1.1 | 3 |
| 152 | Too Few, Too Weak: Conflict of Interest Policies at Canadian Medical Schools. <i>PLoS ONE</i> , 2013, 8, e68633. | 1.1 | 38 |
| 153 | Health Canada and the pharmaceutical industry: a preliminary analysis of the historical relationship. <i>Healthcare Policy</i> , 2013, 9, 22-9. | 0.3 | 3 |
| 154 | New Drugs and Safety. <i>Archives of Internal Medicine</i> , 2012, 172, 1680. | 4.3 | 61 |
| 155 | Of money and trust in medical care redux. <i>Mens Sana Monographs</i> , 2012, 10, 143. | 0.2 | 1 |
| 156 | Harmony in Drug Regulation, but Who's Calling the Tune? An Examination of Regulatory Harmonization in Health Canada. <i>International Journal of Health Services</i> , 2012, 42, 119-136. | 1.2 | 8 |
| 157 | Industry sponsorship and research outcome. , 2012, 12, MR000033. | | 642 |
| 158 | Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. <i>BMJ, The</i> , 2012, 345, e5155-e5155. | 3.0 | 46 |
| 159 | Sponsorship bias in clinical research. <i>International Journal of Risk and Safety in Medicine</i> , 2012, 24, 233-242. | 0.3 | 95 |
| 160 | International comparison of assessments of pharmaceutical innovation. <i>Health Policy</i> , 2012, 105, 221-225. | 1.4 | 16 |
| 161 | Models for financing the regulation of pharmaceutical promotion. <i>Globalization and Health</i> , 2012, 8, 24. | 2.4 | 22 |
| 162 | Pharmaceutical research and development: what do we get for all that money?. <i>BMJ, The</i> , 2012, 345, e4348-e4348. | 3.0 | 168 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications. <i>Science and Engineering Ethics</i> , 2012, 18, 247-261. | 1.7 | 130 |
| 164 | Pharmacovigilance in Europe and North America: Divergent approaches. <i>Social Science and Medicine</i> , 2012, 75, 165-170. | 1.8 | 23 |
| 165 | The cost of drug development: A systematic review. <i>Health Policy</i> , 2011, 100, 4-17. | 1.4 | 379 |
| 166 | The danger of imperfect regulation: OxyContin use in the United States and Canada. <i>International Journal of Risk and Safety in Medicine</i> , 2011, 23, 233-240. | 0.3 | 28 |
| 167 | Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?. <i>BMC Health Services Research</i> , 2011, 11, 64. | 0.9 | 11 |
| 168 | Beyond patents: The GAVI Alliance, AMCs and improving immunization coverage through public sector vaccine production in the global south. <i>Hum Vaccin</i> , 2011, 7, 291-292. | 2.4 | 12 |
| 169 | Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1008. | 3.8 | 121 |
| 170 | Ban Drug Advertisements. <i>Canadian Journal of Emergency Medicine</i> , 2011, 13, 297. | 0.5 | 0 |
| 171 | Coverage with Evidence Development for Pharmaceuticals: A Policy in Evolution?. <i>International Journal of Health Services</i> , 2011, 41, 337-354. | 1.2 | 12 |
| 172 | The association between a journal's source of revenue and the drug recommendations made in the articles it publishes. <i>Cmaj</i> , 2011, 183, 544-548. | 0.9 | 16 |
| 173 | Does family medicine have a professional obligation to play a leading role in pharmaceutical industry-sponsored drug research?: no. <i>Canadian Family Physician</i> , 2011, 57, 871, 873, 875, 877; discussion e276, e278. | 0.1 | 0 |
| 174 | Prohibiting or "managing" conflict of interest? A review of policies and procedures in three European drug regulation agencies. <i>Social Science and Medicine</i> , 2010, 70, 643-647. | 1.8 | 41 |
| 175 | Pharmaceutical innovation: Can we live forever? A commentary on Schnittker and Karandinos. <i>Social Science and Medicine</i> , 2010, 70, 972-973. | 1.8 | 1 |
| 176 | One step forward, one step sideways? Expanding research capacity for neglected diseases. <i>BMC International Health and Human Rights</i> , 2010, 10, 20. | 2.5 | 15 |
| 177 | Statistics in drug advertising: what they reveal is suggestive what they hide is vital. <i>International Journal of Clinical Practice</i> , 2010, 64, 1015-1018. | 0.8 | 6 |
| 178 | Drug safety and Health Canada. <i>International Journal of Risk and Safety in Medicine</i> , 2010, 22, 41-53. | 0.3 | 4 |
| 179 | Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. <i>PLoS Medicine</i> , 2010, 7, e1000352. | 3.9 | 385 |
| 180 | Canada's Access to Medicines Regime: Promise or Failure of Humanitarian Effort?. <i>Healthcare Policy</i> , 2010, 5, 40-8. | 0.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Gardasil® - The New HPV Vaccine: The Right Product, the Right Time? A Commentary. <i>Healthcare Policy</i> , 2010, 5, 26-36. | 0.3 | 3 |
| 182 | Institutional financial conflicts of interest policies at Canadian academic health science centres: a national survey. <i>Open Medicine</i> , 2010, 4, e134-8. | 1.5 | 5 |
| 183 | Le JCMU et les publicités pharmaceutiques : il est temps d'en finir. <i>Canadian Journal of Emergency Medicine</i> , 2009, 11, 380-384. | 0.5 | 0 |
| 184 | Pricing of multiple dosage prescription medications: An analysis of the Ontario Drug Benefit Formulary. <i>Health Policy</i> , 2009, 91, 142-147. | 1.4 | 8 |
| 185 | CJEM and pharmaceutical advertisements: it's time for an end. <i>Canadian Journal of Emergency Medicine</i> , 2009, 11, 375-379. | 0.5 | 5 |
| 186 | Indicators for measuring mental health: towards better surveillance. <i>Healthcare Policy</i> , 2009, 5, e177-86. | 0.3 | 15 |
| 187 | National Evaluation of Policies on Individual Financial Conflicts of Interest in Canadian Academic Health Science Centers. <i>Journal of General Internal Medicine</i> , 2008, 23, 1896-1903. | 1.3 | 11 |
| 188 | Drug Approval Times and User Fees. <i>Pharmaceutical Medicine</i> , 2008, 22, 1-11. | 1.0 | 2 |
| 189 | Clinical Trials in Canada: Whose Interests are Paramount?. <i>International Journal of Health Services</i> , 2008, 38, 525-542. | 1.2 | 6 |
| 190 | Physician awareness of diagnostic and nondrug therapeutic costs: A systematic review. <i>International Journal of Technology Assessment in Health Care</i> , 2008, 24, 158-165. | 0.2 | 79 |
| 191 | The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States. <i>PLoS Medicine</i> , 2008, 5, e1. | 3.9 | 343 |
| 192 | Poor Reporting of Scientific Leadership Information in Clinical Trial Registers. <i>PLoS ONE</i> , 2008, 3, e1610. | 1.1 | 32 |
| 193 | Medications for obesity. <i>Canadian Family Physician</i> , 2008, 54, 848-9; author reply 849-50. | 0.1 | 0 |
| 194 | Medicine reimbursement recommendations in Canada, Australia, and Scotland. <i>American Journal of Managed Care</i> , 2008, 14, 581-8. | 0.8 | 25 |
| 195 | Physician Awareness of Drug Cost: A Systematic Review. <i>PLoS Medicine</i> , 2007, 4, e283. | 3.9 | 203 |
| 196 | Educating Health Professionals about Drug and Device Promotion: Authors' Reply. <i>PLoS Medicine</i> , 2007, 4, e88. | 3.9 | 0 |
| 197 | Is Australia's National Medicines Policy Failing? the Case of Cox-2 Inhibitors. <i>International Journal of Health Services</i> , 2007, 37, 735-744. | 1.2 | 1 |
| 198 | 'Linkage' pharmaceutical evergreening in Canada and Australia. <i>Australia and New Zealand Health Policy</i> , 2007, 4, 8. | 2.2 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Regulating Drugs for Effectiveness and Safety: A Public Health Perspective. <i>Medical Care</i> , 2007, 45, 911. | 1.1 | 1 |
| 200 | Of Money And Trust In Biomedical Care. <i>Mens Sana Monographs</i> , 2007, 5, 7. | 0.2 | 2 |
| 201 | Different conclusions about memantine. <i>Canadian Family Physician</i> , 2007, 53, 403-4; author reply 404. | 0.1 | 1 |
| 202 | Notice of compliance with conditions: a policy in limbo. <i>Healthcare Policy</i> , 2007, 2, 114-22. | 0.3 | 14 |
| 203 | The secret things belong unto the Lord our God: secrecy in the pharmaceutical arena. <i>Medicine and Law</i> , 2007, 26, 417-30. | 0.0 | 4 |
| 204 | A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences. <i>Health Policy</i> , 2006, 79, 214-220. | 1.4 | 6 |
| 205 | Bigger and Better: How Pfizer Redefined Erectile Dysfunction. <i>PLoS Medicine</i> , 2006, 3, e132. | 3.9 | 67 |
| 206 | Educating Health Professionals about Drug and Device Promotion: Advocates' Recommendations. <i>PLoS Medicine</i> , 2006, 3, e451. | 3.9 | 34 |
| 207 | Adverse drug events: counting is not enough, action is needed. <i>Medical Journal of Australia</i> , 2006, 184, 315-316. | 0.8 | 30 |
| 208 | Commercial influence and the content of medical journals. <i>BMJ: British Medical Journal</i> , 2006, 332, 1444-1447. | 2.4 | 77 |
| 209 | Is there still a role for spontaneous reporting of adverse drug reactions?. <i>Cmaj</i> , 2006, 174, 191-192. | 0.9 | 43 |
| 210 | Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices. <i>Cmaj</i> , 2006, 174, 1120-1121. | 0.9 | 16 |
| 211 | Relationship Between Pharmaceutical Company User Fees and Drug Approvals in Canada and Australia: A Hypothesis-Generating Study. <i>Annals of Pharmacotherapy</i> , 2006, 40, 2216-2222. | 0.9 | 10 |
| 212 | Are drugs too expensive in Canada? Yes. <i>Canadian Family Physician</i> , 2006, 52, 573-6, 578-81. | 0.1 | 2 |
| 213 | Rebuttal: are drugs too expensive in Canada?. <i>Canadian Family Physician</i> , 2006, 52, 841-2, 843-5. | 0.1 | 1 |
| 214 | Introduction of direct-to-consumer advertising of prescription drugs in Canada: An opinion survey on regulatory policy. <i>Research in Social and Administrative Pharmacy</i> , 2005, 1, 310-330. | 1.5 | 9 |
| 215 | Implications of Pharmaceutical Industry Funding on Clinical Research. <i>Annals of Pharmacotherapy</i> , 2005, 39, 194-197. | 0.9 | 50 |
| 216 | Intellectual Property Rights and the Canadian Pharmaceutical Marketplace: Where Do We Go from Here?. <i>International Journal of Health Services</i> , 2005, 35, 237-256. | 1.2 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Drug withdrawals from the Canadian market for safety reasons, 1963-2004. Cmaj, 2005, 172, 765-767. | 0.9 | 61 |
| 218 | Foreign free riders and the high price of US medicines. BMJ: British Medical Journal, 2005, 331, 958-960. | 2.4 | 59 |
| 219 | Transparency in drug regulation: Mirage or oasis?. Cmaj, 2004, 171, 1363-1365. | 0.9 | 16 |
| 220 | Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence. International Journal of Health Services, 2004, 34, 101-122. | 1.2 | 160 |
| 221 | The effect of generic competition on the price of brand-name drugs. Health Policy, 2004, 68, 47-54. | 1.4 | 79 |
| 222 | Stop the Merry-Go-Round. HealthcarePapers, 2004, 4, 29-34. | 0.2 | 1 |
| 223 | Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ: British Medical Journal, 2003, 326, 1167-1170. | 2.4 | 1,733 |
| 224 | The siren call of new drugs. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 513-515. | 0.7 | 4 |
| 225 | Safeguarding the Quality of Clinical Research. AMA Journal of Ethics, 2003, 5, 216. | 0.4 | 1 |
| 226 | Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No. Journal of Public Policy and Marketing, 2002, 21, 194-201. | 2.2 | 106 |
| 227 | The pharmaceutical industry as a medicines provider. Lancet, The, 2002, 360, 1590-1595. | 6.3 | 133 |
| 228 | Assessing the quality of drug detailing. Journal of Clinical Epidemiology, 2002, 55, 825-832. | 2.4 | 19 |
| 229 | New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials?. Canadian Family Physician, 2002, 48, 1487-92. | 0.1 | 3 |
| 230 | Effects of restrictive formularies in the ambulatory care setting. American Journal of Managed Care, 2002, 8, 69-76. | 0.8 | 17 |
| 231 | To the editor:. Journal of Emergency Medicine, 2001, 20, 415. | 0.3 | 1 |
| 232 | Everyday experiences of implicit rationing: comparing the voices of nurses in California and British Columbia. Sociology of Health and Illness, 2001, 23, 633-653. | 1.1 | 8 |
| 233 | Double standards: double jeopardy. Pharmacoepidemiology and Drug Safety, 2000, 9, 289-290. | 0.9 | 3 |
| 234 | Letters to the Editor: Click, click: the internet and prescription drugs. Australian Prescriber, 2000, 23, 73-74. | 0.5 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Esophageal detector devices and children. Canadian Journal of Emergency Medicine, 1999, 1, 162-163. | 0.5 | 0 |
| 236 | Hear No Secrets, See No Secrets, Speak No Secrets: Secrecy in the Canadian Drug Approval System. International Journal of Health Services, 1999, 29, 167-178. | 1.2 | 2 |
| 237 | Direct-To-Consumer Advertising. Disease Management and Health Outcomes, 1999, 5, 273-283. | 0.3 | 11 |
| 238 | Improving the Appropriateness of Physician Prescribing. International Journal of Health Services, 1998, 28, 253-267. | 1.2 | 36 |
| 239 | After compulsory licensing: coming issues in Canadian pharmaceutical policy and politics. Health Policy, 1997, 40, 69-80. | 1.4 | 21 |
| 240 | The Timeliness of New Drug Approvals in Canada: A Rejoinder. International Journal of Health Services, 1995, 25, 167-171. | 1.2 | 1 |
| 241 | Canadian Marketing Codes: How Well are They Controlling Pharmaceutical Promotion?. International Journal of Health Services, 1994, 24, 91-104. | 1.2 | 9 |
| 242 | Who Needs Faster Drug Approval Times in Canada: The Public or the Industry?. International Journal of Health Services, 1994, 24, 253-264. | 1.2 | 12 |
| 243 | Pharmaceuticals, Patents, and Politics: Canada and Bill C-22. International Journal of Health Services, 1993, 23, 147-160. | 1.2 | 27 |
| 244 | Pharmaceutical Promotion in the Third World. Journal of Drug Issues, 1992, 22, 417-453. | 0.6 | 11 |
| 245 | Prescribing and Drug Costs in the Province of Ontario. International Journal of Health Services, 1992, 22, 471-487. | 1.2 | 13 |
| 246 | Doctors and Detailers: Therapeutic Education or Pharmaceutical Promotion?. International Journal of Health Services, 1989, 19, 663-679. | 1.2 | 78 |
| 247 | The Medical Profession and the Pharmaceutical Industry: An Unhealthy Alliance. International Journal of Health Services, 1988, 18, 603-616. | 1.2 | 11 |
| 248 | PHARMACEUTICAL PROMOTION IN NEW ZEALAND. Community Health Studies, 1988, 12, 264-272. | 0.0 | 3 |
| 249 | Pharmaceutical Promotion in Canada: Convince Them or Confuse Them. International Journal of Health Services, 1987, 17, 77-89. | 1.2 | 22 |
| 250 | The Miracle of the Empty Beds: A History of Tuberculosis in Canada. Labour/Le Travail, 1980, 6, 233. | 0.0 | 9 |
| 251 | Pharmaceutical Research and Development: What Do We Get for All that Money?. SSRN Electronic Journal, 0, , . | 0.4 | 5 |
| 252 | The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia. SSRN Electronic Journal, 0, , . | 0.4 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 253 | Information and promotional strategies by pharmaceutical companies for clinicians. The Cochrane Library, 0, , . | 1.5 | 0 |
| 254 | The Pharmaceutical Industry in Contemporary Capitalism. Monthly Review, 0, , 37-50. | 0.3 | 18 |
| 255 | Evolution of Physician-Industry Relationships in Producing Knowledge of Drug Therapy - Comparison of the United States and Finland. SSRN Electronic Journal, 0, , . | 0.4 | 0 |